CLOV · Clover Health Investments

The thesis

Clover Health's earnings are improving as its Medicare Advantage membership grows, and the third-quarter report of 4 November 2026 confirmed that with a profit beat and a narrower, higher full-year range. The Eleventh Circuit appeal by the Centers for Medicare & Medicaid Services (CMS) over the court-ordered Star Rating recalculation still decides whether the high ratings last. The shares closed at $4.93 on 10 November 2026, 8.9% below the $5.41 52-week high, with a 14-day relative strength index (RSI) of 53.7.

Clover reported third-quarter revenue of $759.3 million, up 52.9% year over year, with GAAP (generally accepted accounting principles) net income of $6.4 million, per a Finviz summary of the release. The company named Joseph Clay Thornton chief financial officer effective 4 November 2026. UBS raised its price target to $5.50 from $4.75 on 6 November 2026 and kept a Neutral rating.

The story is well known: the court ruling (10 June 2026) and the 2027 Star Ratings (8 October 2026) are well known, and the 4 November 2026 report added an incremental guidance raise rather than a new story. The rating moves up to medium because the quarter and the early 2027 enrollment commentary strengthen the earnings case. The appeal remains unresolved and can still reverse the rating remedy.

Bullish and bearish views on Clover Health Investments, Corp.

The bull case on Clover Health Investments, Corp. (CLOV), in brief: profit and growth arrived together. The bear case: the appeal can undo the remedy.

Bull case

• Profit and growth arrived together. Third-quarter revenue was $759.3 million, up 52.9%, and GAAP net income was $6.4 million against a $24.4 million loss a year earlier, per a Finviz summary of the 4 November 2026 release. Earnings per share of $0.01 beat a consensus loss of $0.01 (company-news headlines, 4 November 2026).
• Guidance moved up again. Full-year 2026 revenue is now $2.97–3.00 billion (prior $2.92–3.00 billion), adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) $75–85 million (prior $70–85 million) and GAAP net income $25–35 million (prior $20–35 million), per the 4 November 2026 release as reported by Fierce Healthcare. Management expects 2026 to be Clover's first full year of GAAP profit.
• Medical costs improved. The insurance benefits expense ratio fell 240 basis points to 91.1%, and consolidated gross profit rose 77% to $130 million, per the Finviz summary of the third-quarter release. Cash and investments were $513 million with no debt.
• Early 2027 enrollment is described as strong. Management cited Braven's exit from New Jersey and large national carriers pulling back from $0-premium preferred provider organization (PPO) plans, per the Finviz summary. Annual enrollment runs 15 October to 7 December 2026, and Clover gave no formal 2027 guidance.
• Analysts are lifting targets. UBS raised its Neutral target to $5.50 on 6 November 2026. Needham initiated with Buy and a $6 target on 28 October 2026, and Deutsche Bank set a $6.00 target on 10 September 2026, per Stock Analysis.

Bear case

• The appeal can undo the remedy. CMS filed notice of appeal on 21 July 2026, per Healthcare Dive, and the Georgetown litigation tracker lists the government's opening brief dated 31 August 2026. A vacated judgment would remove the court-ordered rating and the 5-Star PPO result for 2027, which Clover's 8 October 2026 release says would be 4.5 Stars with the 20 court-covered measures counted.
• Earnings quality is thin. The Finviz summary says about $11 million of other income helped the third quarter, including roughly $4 million from an investment valuation adjustment, and that stock-based compensation fell to $8.0 million from $26.1 million. That article's view is that the quarter would show an operating loss without the other-income line.
• The fourth quarter is guided to a loss. The Finviz summary says the guidance ranges imply a fourth-quarter GAAP net loss of roughly $27–37 million, reflecting seasonality and enrollment spending. Management also said a large 2027 new-member cohort will weigh on near-term earnings.
• Competition is arriving. The Finviz summary names Devoted Health entering New Jersey and elevated outpatient utilization, which it says is within Clover's outlook. Elevance filed a rival rating suit on 6 July 2026, and CMS reported on 8 October 2026 that 37% of Medicare Advantage drug-plan contracts earned four or more Stars.
• Contract concentration is extreme. About 98% of members are in the flagship PPO, per the Fierce Healthcare summary of the third quarter. One rating decision therefore governs nearly all of the business.

Price setup

The shares closed at $4.93 on 10 November 2026, 9.8% higher over three months, with an RSI of 53.7 (adjusted daily closes). The $5.41 52-week high is 8.9% above that close and is the nearest prior ceiling. The Finviz summary put the shares at $4.29 before the 4 November 2026 report and 21% above their 200-day moving average of $3.55, so most of the post-report gain sits above an average that is itself rising.

Crowding evidence is moderate. Retail attention is high: the shares rose 18.9% in one session on 10 June 2026, and the register is retail-heavy. Needham's and Deutsche Bank's $6 targets and UBS's $5.50 target all sit above the close. The next earnings report is not due inside 30 days.

Catalysts ahead

• 7 December 2026: Medicare annual enrollment period ends (it began 15 October 2026). Closes the window in which Clover's 2027 plans compete for members at the higher Star ratings; results appear only in later reports.
• Undated: Eleventh Circuit briefing in the CMS appeal of Clover Insurance Company v. HHS; no ruling is expected within 30 days. A ruling decides whether the court-ordered rating and the 2027 5-Star PPO result stand.
• ~February 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether the fourth-quarter loss implied by full-year guidance lands in range.

What would change the view

A weekly close below $4.00, which would break the post-ruling recovery and fall under the pre-report price. An Eleventh Circuit order vacating the judgment, or an official reversal of the 4.5-Star and 5-Star PPO ratings, would also end the case.

The risks this note tracks, each with what would confirm it:

• An appellate reversal removes the court-ordered rating remedy and the 2027 5-Star PPO result built on it. Confirmed by: an Eleventh Circuit order vacating Clover's judgment, or an official reversal of the 4.5-Star and 5-Star PPO ratings.
• Earnings quality is thin: the third-quarter GAAP profit leaned on other income and lower stock-based compensation. Confirmed by: a fourth-quarter or first-quarter report in which operating results stay negative once other income is excluded.
• A large 2027 new-member cohort and new competitors in New Jersey weigh on near-term earnings. Confirmed by: management guidance for 2027 below current expectations, or a medical benefits ratio above the 91.1% reported for the third quarter of 2026.
• Rival lawsuits and widespread high ratings dilute the bonus-payment edge the ruling gave Clover. Confirmed by: court wins for Elevance, SCAN or Alignment that lift competitors' ratings, or a Clover membership shortfall after the 2027 enrollment window.

What it trades with

Clover trades with other Medicare Advantage insurers on rating and reimbursement news, and its Star Rating litigation is followed by rivals that filed similar suits, including Elevance (6 July 2026). Appeals-court news for any Star Ratings case can move the group together. The shares also react to broad small-cap and retail-momentum flows, as the 18.9% single-session rise on 10 June 2026 showed.